April 30, 2015
Kellogg offers new clinical trial for dry eye sufferers
ANN ARBOR—More than 33 million Americans—roughly one in eight adults—suffer from dry eye disease. While permanent vision loss from this disease is uncommon, it is a chronic condition that can cause pain, ulcers, scars on the cornea, and some loss of vision.
Because so many people suffer from this disease, cornea specialist Roni M. Shtein, M.D., M.S., is leading a Kellogg research team in a new study—the Dry Eye Assessment and Management Trial, or DREAM—in hopes of finding a new treatment option.
The DREAM study will evaluate the effectiveness and safety of using supplements of omega-3 fatty acids to treat the symptoms of moderate to severe dry eye disease. Currently, these over-the-counter nutritional supplements are used to treat high levels of fat in the blood.
“Dry eye disease is extremely common and it leads many patients to seek care from their eye care professional,” says Dr. Shtein. “The DREAM study is the first major, non-pharmaceutical-funded trial on dry eye disease and we at Kellogg are excited to be a part of it.”
Participation in the study is for one year and, if eligible, patients can extend their participation for an additional year. Dr. Shtein and her team hope to enroll 50 patients here at Kellogg, with the national goal of 600 patients. Kellogg is one of several national eye centers participating in this study, which is led by the University of Pennsylvania and funded by the National Eye Institute, a branch of the National Institutes of Health.
For more information, contact clinical research coordinator Munira Hussain, M.S., CCRP, at 734.647.8397 or email@example.com.